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ABSTRACT
The immune system protects organisms from
foreign proteins, peptide epitopes and a multitude
of chemical compounds. Among these, haptens are
small molecules, eliciting an immune response when
conjugated with carrier molecules. Known haptens
are xenobiotics or natural compounds, which can
induce a number of autoimmune diseases like con-
tact dermatitis or asthma. Furthermore, haptens are
utilized in the development of biosensors, immuno-
modulators and new vaccines. Although hapten-
induced allergies account for 6–10% of all adverse
drug effects, the understanding of the correlation
between structural and haptenic properties is rather
fragmentary. We have developed a manually curated
hapten database, SuperHapten, integrating informa-
tion from literature and web resources. The current
version of the database compiles 2D/3D structures,
physicochemical properties and references for about
7500 haptens and 25,000 synonyms. The commercial
availability is documented for about 6300 haptens
and 450 related antibodies, enabling experimental
approaches on cross-reactivity. The haptens are
classified regarding their origin: pesticides, herbi-
cides, insecticides, drugs, natural compounds, etc.
Queries allow identification of haptens and associ-
ated antibodies according to functional class, carrier
protein, chemical scaffold, composition or structural
similarity. SuperHapten is available online at http://
bioinformatics.charite.de/superhapten.
INTRODUCTION
Today, many aspects of the immune system like receptor-
mediated signalling or induction of autoimmune diseases
are only partly understood (1–3). Nevertheless, the substan-
tial progress in the development of new vaccines (4,5) or
therapeutic antibodies (6) demonstrates the great impact of
immunological research on drug design and immune therapy.
Although not antigenic by themselves, haptens interact with
T-cell receptors or speciﬁc antibodies when conjugated to a
larger antigenic molecule, usually a carrier protein. T-cells
recognize haptens which are bound to the major histocom-
patibility complex (MHC) presented on the surface of vari-
ous cell types. In contrast, hapten recognition by B-cells is
mediated by receptors located on their membranes. Once
they are activated, B-cells differentiate into Ig-secreting
plasma cells. Such cells are able to produce highly speciﬁc
antibodies that have the capability to bind haptens without
carrier conjugation (7).
Speciﬁc antibody recognition is utilized in the development
of biosensors (8), catalytic antibodies (9), immunomodulators
(10) or new vaccines (11). However, an immune response is
not always favourable. Natural and synthetic compounds in
food or cosmetic products can cause skin inﬂammation
(12), asthma and other allergic symptoms (13). Even though
several mechanisms are discussed to be operative in the
pathogenesis, immunogenic compounds are capable of elicit-
ing autoimmune diseases like hepatocellular hepatitis (14) or
systemic lupus erythematosus (15). It is estimated that drug
allergies account for 6–10% of all adverse drug effects (16).
Many databases exist that provide diverse information for
immunology. The International Immunogenetics Information
System (17) consists of databases, online-tools and Web
resources regarding various immunological aspects. Exten-
sive information is also provided by the HIV Molecular
Immunology Database (http://www.hiv.lanl.gov/content/
immunology). Data relating to antigenic epitopes are col-
lected in the databases JenPep (18), AntiJen (19) and Epitome
(20). Furthermore the databases Kabat (21), MHCBN (22),
Bcipep (23) and FIMM (24) provides comprehensive
information about MHC binding peptides, B-cell epitopes
or antibody sequences.
Haptens have rarely been subject to an extensive descrip-
tion. Recently, a large manually curated immune epitope
database (IEDB) was published (25). Although the database
focuses on antigenic peptides, it contains 91 haptens. Much
more haptens are described within the HaptenDB (26), a col-
lection of approximately 1000 haptens with its main focus on
the underlying immunochemical assays. It contains informa-
tion about the assay method, conjugation ratio of haptens and
carrier molecules, sensitivity and speciﬁcity of the system or
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is very helpful to get an overview of the performed immuno-
logic experiments, we noticed that many important immuno-
logic compounds are missing. For example, drugs such as
aspirin or beta adrenergic antagonists are capable of eliciting
severe autoimmune diseases like bronchial asthma (27) or
Psoriasis (28). Chlorated benzenes present in pesticides, sol-
vents and lubricants are frequently described as haptens but
apparently not incorporated within the HaptenDB. While
the authors processed in detail the data of approximately
250 hapten-related articles, a large proportion of described
haptens and associated immunologic articles is ignored. Fur-
thermore, information about the availability of the described
haptens and antibodies will be helpful in case a described
immunoassay is to be reproduced.
To overcome these problems, we have performed a more
extensive semi-automatic literature screening, resulting in a
comprehensive dataset.
DATABASE DESCRIPTION
SuperHapten currently contains 7257 different haptens and
references to about 10,000 immunologic articles. The basic
application of the database is the identiﬁcation of compounds
that elicit immune response. The user interface provides
diverse query types, like searching by hapten name, physico-
chemical properties, industrial use or associated carrier
protein. Figure 1 depicts various query types. A built-in mole-
cule editor allows the user to draw a molecule and to screen
the database for compounds with similar molecular structure.
This feature is of particular interest even if the speciﬁc
requested molecule is not part of the database. Since com-
pounds with high structural similarity frequently exhibit
similar activities (29), this method provides an informative
basis for the identiﬁcation of new immunogenic compounds.
Identiﬁed haptens are displayed by 3D structure and may act
as starting points for further similarity searches. Each com-
pound is provided with a full info page containing synonyms,
molecular properties and references to the underlying litera-
ture. Another important aspect to assist immunologists is
the availability of the haptens for further experiments. We
have checked whether the haptens are commercially obtain-
able and provided 6279 compounds with ordering codes
and external links to suppliers. Similarly, the ordering
information of 453 hapten related antibodies was determined
and included within the database. This procedure may avoid
exhausting in vitro antibody generations if speciﬁc antibodies
are required. Carrier proteins are annotated with UNIPROT-
ID, PDB-structure and underlying references to literature.
Furthermore, we have checked whether the annotated haptens
are structurally resolved in complex with antibodies, carriers
or other proteins. The corresponding PDB cross references
are included on the hapten related info pages. Some haptens
were identiﬁed, which are assured to be MHC-mediated.
These 46 haptens are speciﬁed separately and directly retriev-
able. Table 1 speciﬁes some key numbers of the database
content.
Another intention was to allow immunologists an overview
of known immunogenic compounds. For that purpose, the
haptens were compared all against all and clustered by
structural similarity. The resulting 154 clusters containing at
least eight similar compounds were manually ordered to
obtain a hierarchical compound tree. Each node was named
according to the chemistry of the included compounds. For
example, halogenated chemicals are frequently responsible
for environmental skin diseases (30). About 800 references
to articles are retrievable, which describe an immunologic
response to halogenated compounds. By the same procedure,
chemical classes like sulfurones or triazines are easily acces-
sible. The presented cluster tree could potentially allow
researchers to analyse the relationship between molecular
structure and immunogenic effect. Exemplarily, Table 2
shows seven chemicals according to different compound
groups.
METHODS
Haptens were collected from literature and various web
resources. The abstracts of the literature database PubMed
were ﬁltered for relevant immunologic articles, using speciﬁc
keywords. The 15,000 abstracts thus obtained were screened
against names and synonyms of 3 million chemical com-
pounds as well as a distinct set of substrings of IUPAC names.
The text passages containing matches were manually
curated by a scientiﬁc team that conﬁrmed the matching
and analysed whether the identiﬁed compound was recog-
nized by antibodies or T-cell receptors. About 200 full text
review articles were subjected to the same procedure. The
resulting 1600 haptens formed the conﬁrmed basic dataset.
Two web resources were checked, the DIMDI contact
allergen database (http://www.dimdi.de/static/en/db/dbinfo/
dbkurz/ka00.htm) and the HaptenDB (26). Additional
400 compounds were detected and included within the Super-
Hapten. Each compound of the basic dataset was translated
into a structural ﬁngerprint, using the chemistry development
kit (http://almost.cubic.uni-koeln.de/cdk/). The ﬁngerprint
algorithm follows the approach taken by Daylight (http://
www.daylight.com/dayhtml/doc/theory/). Up to six con-
nected atoms all connectivity paths within the molecule are
determined. For each path, a hash function calculates the
location of a representing bit in a Boolean array. The number
of possible paths is huge and it is not possible to assign a par-
ticular bit to each path, thus a particular bit represents several
paths. The combination of all representing bits of all paths
yields in a speciﬁc pattern or structural ﬁngerprint.
The similarity index used is the Tanimoto coefﬁcient,
which is the number of bit positions set to 1 in both ﬁnger-
prints divided by the number of bit positions set to 1 in at
least one of the ﬁngerprints. If a set bit is considered as a fea-
ture present in the molecule, the Tanimoto coefﬁcient is a
measure of the number of common features in both molecules
(31). A Tanimoto coefﬁcient of >0.85 indicates that two
molecules have similar activities (32). Calculated ﬁngerprints
were used for a further structural screening against 4 million
compounds. In this way, 5248 compounds were detected that
resulted in Tanimoto coefﬁcients of >0.9. These putative hap-
tens are highly probable candidates for eliciting the same
kind of immune response, binding to the same carrier and
being recognised by the same antibodies or T-cells as the
haptens found in literature (29).
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Discovery Studio, (Accelrys Inc., http://www.accelrys.com/
dstudio) and visualized with the free Chime-Plugin from
MDL (available for Windows, SGI, Mac). Linux compatibil-
ity is warranted by a second visualizer, MarvinView
(ChemAxon). The same tool was also used for the built-in
molecule editor that allows structural screening with self-
edited molecules.
For compatibility, our data model are directed to the
schema implemented in the IEDB (25). A diagram of the
database schema is shown at the website. The data are imple-
mented as a relational database on a MySQL server and pub-
licly available at http://bioinformatics.charite.de/superhapten.
Figure 1. Queries and results of the SuperHapten web-interface. Query types: (a) Part of the cluster-tree, showing the structure of the scaffold classification.
Clicking on the nodes expands the branch: monocyclic aromatic compounds ! dinitrobenzene derivatives etc. Clicking on leafs triggers a database search in a
separate window. (b) Text query options including a classification regarding the origin of the haptens. (c) Screenshot of the java applet Marvin which allows
upload or drawing of own structures for similarity searches in the SuperHapten database showing Dinitrophenol. Results (d) Query results with search options for
2D similarity: Dinitrophenol (C6H4N2O5) and 2,4-dinitro-6-methylphenol (C7H6N2O5). The compounds can be rotated (left mouse button), different display
styles are available, structures can be saved (right mouse button) and more detailed information, such as synonymous names and formula or supplier information
can be obtained by use of the FULL INFO button. Further information (e) Antibody and suitable information like supplier, ID and source organism are displayed.
(f) Information on hapten specific carrier protein(s), references, UNIPROT-, PDB-ID etc. (h) Recent scientific references confirming the haptenic effect
including author information and abstract.
Table 1. Key numbers of the database content
Entities
Haptens 7257
Antibodies 453
Carrier proteins 24
References to literature 9670
Hapten subgroups
Confirmed 2009
Putative 5248
Commercially available 6285
Drugs 392
Natural compounds 1397
Pesticides 227
D908 Nucleic Acids Research, 2007, Vol. 35, Database issueTable 2. Examples of haptens classified as drugs, contact allergens or pesticides
Hapten cluster Sample structure Cluster size Properties, industrial use
Drugs
Penicillin and derivatives
N
S
O
O H
O
N H
O
O H
92 used in the treatment of bacterial infections
Warfarin derivatives
O O
OH
O
10 used for the prophylaxis of thrombosis and
embolism in many disorders
Pentahalogenated ethanes (halothane)
F
Br
Cl
F
F
16 its vapour is an inhalational general anaesthetic
Pesticides
Tetra- and pentahalogenated phenols
Cl
Cl
Cl
OH
Cl
Cl
29 synthetic fungicides
Imazamox-related compounds
N
O O
OH
N
N
O
119 used as herbicides
Contact allergens
Naphthol derivatives
O H
O
NH
8 colourless, crystaline solid, used in the
production of dyes
Tartrazines
S
OH
O O
N
N
N N
O
O
O H
S
OH O
O
8 lemon yellow, azo dye, used for food colouring
The cluster size specifies the number of highly similar haptens grouped together.
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By now, the presented database has become a useful tool to
retrieve information about speciﬁc immunogenic compounds,
or to get an overview of the known substances that elicit
immune responses. The KEGG-pathway analysis of single
haptenic compounds revealed that their synthesis is exclu-
sively performed by bacterial enzymes (33). SuperHapten
enables systematic approaches on the position of haptens in
metabolic or signalling networks. The included data on pur-
chasability of haptens and related antibodies will enable sys-
tematic experimental approaches on the relation between
structural similarity and cross-reactivity.
Furthermore, structure comparisons of self-edited mole-
cules to the annotated haptens may allow a ﬁrst rough
estimation of the potential immunogenicity of new chemicals.
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